Related Experiment Video

Updated: May 27, 2026

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Statin treatment and gene expression of anti-atherogenic factor C-type natriuretic peptide system in stenotic aortic

Tuomas Peltonen1, Pasi Ohtonen, Juha Näpänkangas

  • 1Institution of Biomedicine, Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, Finland.

The Journal of Heart Valve Disease
|November 10, 2011
PubMed

Insights

The C-type natriuretic peptide (CNP) system is downregulated in aortic valve stenosis (AS). Gene expression of CNP and its receptor NPR-B was lower in AS valves, with no difference between statin-treated and untreated patients.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Atherosclerosis Pathogenesis

Background:

  • Aortic valve calcification shares characteristics with atherosclerosis, involving endothelial dysfunction.
  • The C-type natriuretic peptide (CNP) system plays a role in vascular atherosclerosis and is downregulated in aortic valve stenosis (AS).

Purpose of the Study:

  • To investigate the gene expression of the CNP system, including CNP and its receptor natriuretic peptide receptor type B (NPR-B), in human aortic valves.
  • To compare CNP system gene expression in AS patients receiving statin treatment versus those not receiving statins.

Main Methods:

  • Gene expression analysis using reverse transcription-polymerase chain reaction (RT-PCR).
  • Comparison of CNP and NPR-B mRNA levels in aortic valves from normal controls, patients with aortic regurgitation (AR), and patients with AS (n=108 total).

Main Results:

  • CNP mRNA levels were significantly lower (89%) in stenotic valves compared to AR valves (p=0.022).
  • NPR-B mRNA levels were significantly lower in stenotic valves compared to control (62%, p<0.001) and AR valves (54%, p=0.002).
  • No significant difference in CNP and NPR-B levels was observed between statin-treated and untreated AS patients.

Conclusions:

  • The gene expression of the anti-atherogenic CNP system does not differ between statin-treated and non-statin-treated patients with AS.
  • These findings align with existing clinical trial data for statin efficacy in AS.
Abstract

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...